The clinical pharmacology of biotechnology products

Autor

Any de publicació

1991

No disponible

Marcus M. Reidenberg, del Departament de Farmacologia i Medicina de la Facultat de Medicina de la Universitat Cornell a Nova York, és l’editor d’aquest volum número 4 de la sèrie Esteve Foundation Symposia. Les noves tècniques de biologia molecular i cel•lular presenten diverses oportunitats per al desenvolupament de nous agents per al diagnòstic, el tractament i la prevenció de malalties. Com extrapolar el potencial de la moderna ciència biomèdica a la realitat per poder millorar la salut de les persones és l’objectiu dels farmacòlegs clínics, físics i investigadors de la nova biologia que es van reunir en el simposi internacional organitzat per la Fundació Dr. Antoni Esteve l’octubre de 1990.

Capítols
Introduction	M.M. Reidenberg	[wpdm id=145 type=”btn”]
List of participants		[wpdm id=146 type=”btn”]
1. Purification of Proteins: Converting a culture broth into a medicine	R.G. Werner	[wpdm id=123 type=”btn”]
2. Human insulin and its modifications	J.A. Galloway / R.E. Chance / K.S.E. Su	[wpdm id=124 type=”btn”]
3. the use of recombinant proteins in Aids research: Developtment of a CD4/GP120 binding assay	J. Mous / C. Manzoni / L. Dirckx	[wpdm id=125 type=”btn”]
4. FGF receptors as targets for drug development	C.A. Dionne / M. Jaye / J. Schlessinger	[wpdm id=126 type=”btn”]
5. Development of antagonists for IFNy and TNF	M. Steinmetz	[wpdm id=127 type=”btn”]
6. Proteins in search of a disease	L. Gauci	[wpdm id=128 type=”btn”]
7. Absorption of therapeutic peptides	B.R. Meyer	[wpdm id=129 type=”btn”]
8. Pharmacokinetics of human tissue-type plasminogen activator	P. Tanswell / E. Seifried / J. Krause	[wpdm id=130 type=”btn”]
9. Role of the Kidney in Eliminating Proteins and Peptides	D.C. Brater	[wpdm id=131 type=”btn”]
10. Possible problemas associated with Cytokine contamination of biotechnology products	A. Gearing / M. Wadhwa / R. Thorpe	[wpdm id=132 type=”btn”]
11. Selection of animal species and length of toxicity studies with recombinant proteins. Review of industry and regulators\’ approach and case history of Rec-Hirudin	P. Graepel / F. Pfannkuch / R. Hess	[wpdm id=133 type=”btn”]
12. Toxicological development of hematopoietic growth factors	H. Ronneberger	[wpdm id=134 type=”btn”]
13. Meaningful evaluation of biotechnology products	P. Juul	[wpdm id=135 type=”btn”]
14. Biological and clinical response of recombinant interferon gamma in patients with advanced renal cell cancer	W. Aulitzky / G. Gastl / W.E. Aulitzky / J. Prick / C. Huber	[wpdm id=136 type=”btn”]
15. Tissue-Type Plasminogen Activator	H.R. Lijnen / D. Collen	[wpdm id=137 type=”btn”]
16. Erythropoietin	F. Valderrabano	[wpdm id=138 type=”btn”]
17. Clinical Pharmacology of Hirudin (HBW 023)	H.J. Roethig / J.S. Maree / B.H. Meyer	[wpdm id=139 type=”btn”]
18. Therapeutic actions of recombinant human granulocyte-Macrophage colony-stimulating factor (GM-CSF)	A. Ganser / D. Hoelzer	[wpdm id=140 type=”btn”]
19. Potential use of Peptide hormones in sport	J. Segura / R. de la Torre / R. Badia	[wpdm id=141 type=”btn”]
20. Costs of discovering, developing, manufacturing and marketing biotechnology products	W.M. Wardell	[wpdm id=142 type=”btn”]
21. The impact of economic issues on the therapeutic usage of biotechnology products. A view from the hospital	M. Levy / S. Penchas	[wpdm id=143 type=”btn”]
22. Biotechnological products, Can this commodity be afforded?	F. García Alonso	[wpdm id=144 type=”btn”]

2. Human insulin and its modifications
J.A. Galloway / R.E. Chance / K.S.E. Su
Descarregar

10. Possible problemas associated with Cytokine contamination of biotechnology products
A. Gearing / M. Wadhwa / R. Thorpe
Descarregar

19. Potential use of Peptide hormones in sport
J. Segura / R. de la Torre / R. Badia
Descarregar

3. the use of recombinant proteins in Aids research: Developtment of a CD4/GP120 binding assay
J. Mous / C. Manzoni / L. Dirckx
Descarregar

12. Toxicological development of hematopoietic growth factors
H. Ronneberger
Descarregar

20. Costs of discovering, developing, manufacturing and marketing biotechnology products
W.M. Wardell
Descarregar

4. FGF receptors as targets for drug development
C.A. Dionne / M. Jaye / J. Schlessinger
Descarregar

13. Meaningful evaluation of biotechnology products
P. Juul
Descarregar

21. The impact of economic issues on the therapeutic usage of biotechnology products. A view from the hospital
M. Levy / S. Penchas
Descarregar

5. Development of antagonists for IFNy and TNF
M. Steinmetz
Descarregar

14. Biological and clinical response of recombinant interferon gamma in patients with advanced renal cell cancer
W. Aulitzky / G. Gastl / W.E. Aulitzky / J. Prick / C. Huber
Descarregar

22. Biotechnological products, Can this commodity be afforded?
F. García Alonso
Descarregar

6. Proteins in search of a disease
L. Gauci
Descarregar

15. Tissue-Type Plasminogen Activator
H.R. Lijnen / D. Collen
Descarregar

The clinical pharmacology of biotechnology products Introduction
M.M. Reidenberg
Descarregar

7. Absorption of therapeutic peptides
B.R. Meyer
Descarregar

16. Erythropoietin
F. Valderrabano
Descarregar

The clinical pharmacology of biotechnology products List of participants
Descarregar

8. Pharmacokinetics of human tissue-type plasminogen activator
P. Tanswell / E. Seifried / J. Krause
Descarregar

17. Clinical Pharmacology of Hirudin (HBW 023)
H.J. Roethig / J.S. Maree / B.H. Meyer
Descarregar

1. Purification of Proteins: Converting a culture broth into a medicine
R.G. Werner
Descarregar

9. Role of the Kidney in Eliminating Proteins and Peptides
D.C. Brater
Descarregar

18. Therapeutic actions of recombinant human granulocyte-Macrophage colony-stimulating factor (GM-CSF)
A. Ganser / D. Hoelzer
Descarregar